FDA OKs First Drug for Symptoms of Rare Liver Disease in Kids
The FDA approved odevixibat (Bylvay) for treating young children with intense itching caused by progressive familial intrahepatic cholestasis (PFIC), manufacturer Albireo Pharma announced on Tuesday. Odevixibat becomes the first therapy for the rare disease and was approved to treat pruritus in all PFIC subtypes for patients ages 3 months and older. It was described as […]